The precision and effectiveness of nano-diagnostic platforms rely on the deliberate design of advanced nanomaterials, aiming to address the clinical challenge, such as sensitive diagnosis of infectious chorioamnionitis-associated fever (CAM) versus non-infectious epidural-related maternal fever (ERMF), while also expanding the scope of nano-diagnostic technologies to include bio-detection like glycomics, which are cohesively linked to disease but require complex procedures. Here, we designed a hierarchically channeled graphitized nanoarchitecture (HPGC-Z67) as a novel nano-diagnostic platform. HPGC-Z67 features high graphitization and interconnected multi-scale channeled structures that facilitate N-glycan retention and mass transfer in expanded porous channels. Notably, compared to traditional protocol, this HPGC-Z67 platform reduces processing time by about 25 min and cost by approximately CNY 30 per plasma sample, making it suitable for large-scale clinical diagnostics. The HPGC-Z67 nano-diagnostic platform enables sensitive extraction of N-glycan profiles from 150 plasma samples. Notably, two pivotal N-glycans are identified, one sensitive to infectious fever (IF-sensitive) and the other to non-infectious fever (n-IF-sensitive), which together enable simultaneous differentiation of ERMF, CAM, and healthy controls with area under the curve values of 0.965 in the training set and 0.914 in the validation set, respectively. This HPGC-Z67 nano-diagnostic platform advances glycomics towards precise diagnostics and timely clinical intervention.
Lin et al. (Mon,) studied this question.